<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347408</url>
  </required_header>
  <id_info>
    <org_study_id>282617</org_study_id>
    <nct_id>NCT04347408</nct_id>
  </id_info>
  <brief_title>Seroprevalence of SARS-Cov-2 Antibodies in Children</brief_title>
  <official_title>Seroprevalence of SARS-Cov-2 Antibodies in Children - a Prospective Multicentre Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University, Belfast</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belfast Health and Social Care Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University, Belfast</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how&#xD;
      many have antibodies. The aim of this study is to follow a cohort of healthy children over&#xD;
      six months and measure their antibodies to SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronaviruses are non-segmented positive-stranded RNA viruses with a roughly 30 kb genome.&#xD;
      The majority of coronaviruses cause disease in a specific host species but some have infected&#xD;
      humans by cross-species transmission. This process has led to a number of severe outbreaks of&#xD;
      human disease including severe acute respiratory syndrome (SARS) in 2003 and Middle East&#xD;
      respiratory syndrome (MERS) in 2012.&#xD;
&#xD;
      From December 2019 a novel infection &quot;severe acute respiratory syndrome coronavirus 2&quot;&#xD;
      (SARS-CoV-2) was identified in the Wuhan region of China. The infection was identified as the&#xD;
      causal factor in a growing number of severe cases of pneumonia. This disease was subsequently&#xD;
      named coronavirus disease 2019 (COVID-19) by World Health Organisation (WHO). SARS-CoV-2 has&#xD;
      been shown to cause severe disease similar to the previous SARS coronavirus from 2003. Severe&#xD;
      disease is associated with pneumonia and damage to vital organs including lung, heart, liver,&#xD;
      and kidney.&#xD;
&#xD;
      Fortunately SARS-CoV-2 appears to cause only mild, or no, symptoms in children.&#xD;
&#xD;
      The social distancing measures in the United Kingdom include the closure of schools and the&#xD;
      cancelling of routine paediatric clinics. These drastic, but necessary, steps are likely to&#xD;
      have a profound effect on the well-being of children.&#xD;
&#xD;
      This study is required to determine what proportion of children have been exposed to&#xD;
      SARS-Cov-2 and how many, if any, have neutralizing antibodies. The findings from this study&#xD;
      could be used to inform public health decisions regarding the re-opening of schools and other&#xD;
      services vital to the well-being of children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 6, 2020</start_date>
  <completion_date type="Actual">December 13, 2020</completion_date>
  <primary_completion_date type="Actual">December 13, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immunoglobulins (G and M) to SARS-Cov2 in Plasma</measure>
    <time_frame>6 months</time_frame>
    <description>â€¢ Mean antibody titres (IgG/Total antibody) to SARS-CoV-2 in plasma using ROCH/ABBOTT and DIASORIN assays</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">992</enrollment>
  <condition>COVID</condition>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Healthy Children</arm_group_label>
    <description>Healthy children of healthcare workers between 2 and 15 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Covid-19 Antibody testing (IgG and IgM)</intervention_name>
    <description>Antibody testing for previous exposure to Covid-19</description>
    <arm_group_label>Healthy Children</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy children aged from 0 to 15 who are resident in the United Kingdom&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Healthy children of healthcare professionals.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Not currently receiving antibiotics, not admitted to hospital within the last seven days,&#xD;
        not receiving immunosuppressive drugs and never diagnosed with a malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Waterfield, BMBCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University, Belfast</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <zip>BT126BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Children</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Health England</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Health England</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <results_first_submitted>August 10, 2021</results_first_submitted>
  <results_first_submitted_qc>August 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2021</results_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University, Belfast</investigator_affiliation>
    <investigator_full_name>Thomas Waterfield</investigator_full_name>
    <investigator_title>Chief Investigator and Academic Clinical Lecturer</investigator_title>
  </responsible_party>
  <keyword>antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 14, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT04347408/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In total, 1042 potential participants were screened for inclusion, of whom 50 were excluded; 18 were outside the specified age range, 1 met specific exclusion criteria,16 declined consent and 15 did not undergo phlebotomy. In total 992 were enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Children</title>
          <description>Healthy children of healthcare workers between 2 and 15 years of age&#xD;
Covid-19 Antibody testing (IgG and IgM): Antibody testing for previous exposure to Covid-19</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="992"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="992"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Children</title>
          <description>Healthy children of healthcare workers between 2 and 15 years of age&#xD;
Covid-19 Antibody testing (IgG and IgM): Antibody testing for previous exposure to Covid-19</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="992"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="992"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.1" lower_limit="2.03" upper_limit="15.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="992"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="483"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunoglobulins (G and M) to SARS-Cov2 in Plasma</title>
        <description>â€¢ Mean antibody titres (IgG/Total antibody) to SARS-CoV-2 in plasma using ROCH/ABBOTT and DIASORIN assays</description>
        <time_frame>6 months</time_frame>
        <population>Healthy children of healthcare workers between 2 and 15 years of age</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Children</title>
            <description>Healthy children of healthcare workers between 2 and 15 years of age&#xD;
Covid-19 Antibody testing (IgG and IgM): Antibody testing for previous exposure to Covid-19</description>
          </group>
        </group_list>
        <measure>
          <title>Immunoglobulins (G and M) to SARS-Cov2 in Plasma</title>
          <description>â€¢ Mean antibody titres (IgG/Total antibody) to SARS-CoV-2 in plasma using ROCH/ABBOTT and DIASORIN assays</description>
          <population>Healthy children of healthcare workers between 2 and 15 years of age</population>
          <units>Titres</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="992"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abbott SARS-CoV-2 IgG Assay (Index S/C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" lower_limit="4.28" upper_limit="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elecys Roche SARS-CoV-2 (Cut-Off-Index COI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.32" lower_limit="43.24" upper_limit="87.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diasorin Liason SARS-CoV-2 IgM (arbitrary units A/U)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.17" lower_limit="37.99" upper_limit="90.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality, serious and other adverse events were not monitored/assessed.</time_frame>
      <desc>All-cause mortality, serious and other adverse events were not monitored/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>All-cause Mortality, Serious and Other Adverse Events Were Not Monitored/Assessed.</title>
          <description>All-cause mortality, serious and other adverse events were not monitored/assessed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of this study are that all of the children in this study had only mild disease making comparison between severe and mild disease impossible. The children were also recruited from healthcare workers and the prevalence of antibodies is likely to be lower in the general population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr Thomas Waterfield</name_or_title>
      <organization>Queen's University Belfast</organization>
      <phone>028 9024 5133</phone>
      <email>t.waterfield@qub.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

